Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) made significant clinical progress in the first half of its financial year, with strong trial results for its cancer immunotherapy treatments.
The company also strengthened its cash position, raising £11.3mn in December, extending its cash runway to late 2026.
Its SCIB1 cancer vaccine, tested in patients with advanced melanoma, showed promising early results.
At six months, 80% of patients had no disease progression, with 20% achieving a complete response. These results are stronger than those typically seen with existing treatments. A next-generation version, iSCIB1+, is also progressing well, with more trial data expected in late 2025.
Modi-1, another vaccine targeting solid tumours, showed a 43% response rate in head and neck cancer patients, compared to a historical average of 19% with standard treatment. Scancell has also strengthened its intellectual property, securing a US patent for its Moditope technology.
In its antibody division, Scancell received $6 million from Genmab, which exercised its option on a second antibody from the company’s GlyMab platform. Future milestones could bring up to $630mn in further payments.
"I am pleased with the progress achieved by the Company over the period as we drive for further clinical validation through multiple milestones in 2025," said CEO Phil L'Huillier.
The operating loss for the six months ending October 31 was £10.5 million, reflecting the investment being made in research and development.
More importantly, the cash position as of that date was strong with £9.1 million in the bank.